- Home
- VRCA vs CGTX Comparison
VRCA vs CGTX Comparison
Compare VRCA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 94.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRCA | CGTX |
|---|---|---|
| Price | $6.11 | $1.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.00 | $3.33 |
| AVG Volume (30 Days) | 125.6K | ★ 581.5K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $0.22 |
| 52 Week High | $9.82 | $3.83 |
Technical Indicators
Market Signals| Indicator | VRCA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 43.79 |
| Support Level | $5.22 | $1.00 |
| Resistance Level | $6.44 | $1.19 |
| Average True Range (ATR) | 0.46 | 0.07 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 70.51 | 27.78 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.